There is more innovation in cancer research today than ever before. Many of these efforts are disjointed and silo-ed and as a result often do not reach their full potential. If we can capture that potential, there is great opportunity for cancer patients.

Cullinan uniquely applies open innovation to the development of scientific oncology assets. Our approach breaks down silos, encourages new ways of thinking and collaboration, and ultimately turns ideas and inspiration into novel executable therapeutic concepts. Through both internal and external means, we seek to develop first-in-class or best-in-class assets that have the potential to significantly improve the lives of those living with cancer.

Cullinan was formed to advance a growing portfolio of innovative, early-stage assets by capitalizing on the latest scientific breakthroughs. The company is structured as a unique hybrid model that brings together certain aspects of an investment firm with a true operating company. As a result, we think about capital allocation and risk as much as we think about in-vivo results or clinical trial design.

• Access to the world’s earliest stage oncology research through relationships with MPM Capital, academia, and pharma
• Portfolio diversification across platforms, mechanisms and modalities
• Led by a team of veteran oncology researchers, biopharma executives, and experienced entrepreneurs